Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting
Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting
复制标题
DOI：
10.1097/fpc.0000000000000303
复制
发表时间：
2017-11-01
影响因子：
2.6
通讯作者：
Pantelis, Christos
中科院分区：
文献类型：
--
作者：
Bousman, Chad A.;Jaksa, Philip;Pantelis, Christos
目的本研究的目的是系统地评估与精神科处方相关的商业药物遗传学测试，特别关注CYP2D6和CYP2C19星星等位基因覆盖率以及对药物遗传学试验结果报告的共识建议的依从性。比较了20个药物遗传学测试组的等位基因含量，并根据美国疾病控制与预防中心和临床药物遗传学实施中心发布的共识报告建议评估了其测试结果报告结果大多数试验组包括主要的CYP2D6（*2，*4，*5，*10，*17）和CYP2C19（*2，*3，*17）等位基因，但没有两个试验组包含相同的CYP2D6和CYP2C19等位基因组合。在我们评价的20份药物遗传学报告中，没有一份符合所有建议，也没有一份符合所有试验的建议。结论尚未就药物遗传学试验组和药物遗传学结果报告中应包括的CYP2D6和CYP2C19星星等位基因达成共识。需要测试制造商和最终用户之间的合作，以缩小这些基于药物遗传学的决策支持工具的可用性和集成到常规实践之间的差距。版权所有（C）2017威科医疗集团All rights reserved.
Objective The aim of this study was to systematically assess commercial pharmacogenetic tests relevant to prescribing in psychiatry, with specific attention on CYP2D6 and CYP2C19 star allele coverage as well as compliance with consensus recommendations for pharmacogenetic test result reporting.Materials and methods The CYP2D6 and CY2C19 star (*) allele contents of 20 pharmacogenetic test panels were compared and their test results reports were evaluated on the basis of consensus reporting recommendations published by The Centers for Disease Control and Prevention as well as the Clinical Pharmacogenetics Implementation Consortium.Results Most test panels included the major CYP2D6 (*2, *4, *5, *10, *17) and CYP2C19 (*2, *3, *17) alleles, but no two test panels contained the same combination of CYP2D6 and CYP2C19 alleles. Of the 20 pharmacogenetic reports that we evaluated, none fulfilled all the recommendations and no recommendation was fulfilled by all tests.Conclusion Consensus has yet to be reached on which CYP2D6 and CYP2C19 star alleles to include on pharmacogenetic testing panels and pharmacogenetic results reporting could be considerably improved. Collaboration between test manufacturers and end-users is required to narrow the gap between the availability and integration of these pharmacogenetic-based decision-support tools into routine practice. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.